Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome

Objective: To determine the prevalence and characteristics of coronary heart disease (CHD) risk factors in patients with chronic schizophrenia or schizoaffective disorder. Method: We compared individual CHD risk factors and Framingham risk predictions in a group of 240 patients with a large national sample (Canadian Heart Health Survey) matched for age and sex. In addition, we compared rates of the metabolic syndrome (syndrome X) with recently published rates in the US adult population. Results: Compared with the reference population, Framingham 10-year risk of myocardial infarction was greater in the male patients (t3091 = 4.35, P < 0.001) but not in the female patients. Prevalence rates of the metabolic syndrome in the patients (42.6% of men and 48.5% of women) were approximately 2 times published rates in the US adult population. Further, the syndrome appears to occur at a younger age than in the general population. Conclusions: These long-term patients have increased CHD risks best captured by the metabolic syndrome conceptualization coupled with a high rate of cigarette smoking. This characterization is consistent with increased cardiovascular morbidity and decreased life expectancy in both men and women. We underscore the importance of both screening for and treating potentially reversible CHD risk factors in schizophrenia patients.

[1]  J. Critchley,et al.  Smoking cessation for the secondary prevention of coronary heart disease. , 2012, The Cochrane database of systematic reviews.

[2]  P. Thompson,et al.  Physical activity in the prevention of atherosclerotic coronary heart disease , 2003, Current treatment options in cardiovascular medicine.

[3]  C. Pantelis,et al.  Medical comorbidity in schizophrenia , 2003, The Medical journal of Australia.

[4]  S. Marder,et al.  The effects of novel antipsychotics on glucose and lipid levels. , 2002, The Journal of clinical psychiatry.

[5]  J. Newcomer,et al.  Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. , 2002, Archives of general psychiatry.

[6]  D. Henderson.  Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents , 2002, Current diabetes reports.

[7]  D. Kromhout,et al.  Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. , 2002, Circulation.

[8]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[9]  F Vinicor,et al.  The continuing epidemics of obesity and diabetes in the United States. , 2001, JAMA.

[10]  D. Allison,et al.  Antipsychotic-induced weight gain: a review of the literature. , 2001, The Journal of clinical psychiatry.

[11]  D. Taylor,et al.  Atypical antipsychotics and hyperglycaemia , 2001, International clinical psychopharmacology.

[12]  T. Murphy,et al.  Olanzapine and hypertriglyceridemia. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[13]  P. Sparén,et al.  Mortality and causes of death in schizophrenia in Stockholm County, Sweden , 2000, Schizophrenia Research.

[14]  B. Barraclough,et al.  Causes of the excess mortality of schizophrenia. , 2000, The British journal of psychiatry : the journal of mental science.

[15]  D. Allison,et al.  Weight gain from novel antipsychotic drugs: need for action. , 2000, General hospital psychiatry.

[16]  D. Taylor,et al.  Atypical antipsychotics and weightgain — a systematic review , 2000, Acta psychiatrica Scandinavica.

[17]  J. Meyer.  Novel antipsychotics and severe hyperlipidemia , 2000, Schizophrenia Research.

[18]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[19]  A. Mokdad,et al.  The spread of the obesity epidemic in the United States, 1991-1998. , 1999, JAMA.

[20]  J. Markowitz,et al.  Clozapine-associated elevation in serum triglycerides. , 1999, The American journal of psychiatry.

[21]  L. Dixon,et al.  The association of medical comorbidity in schizophrenia with poor physical and mental health. , 1999, The Journal of nervous and mental disease.

[22]  J. Birtwistle,et al.  The unhealthy lifestyle of people with schizophrenia , 1999, Psychological Medicine.

[23]  S. Marder,et al.  Novel antipsychotics and new onset diabetes , 1998, Biological Psychiatry.

[24]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[25]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[26]  C. Bouchard,et al.  A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. , 1996, The American journal of clinical nutrition.

[27]  P. Mortensen,et al.  Mortality and Causes of Death in First Admitted Schizophrenic Patients , 1993, British Journal of Psychiatry.

[28]  D. Goff,et al.  Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. , 1992, The American journal of psychiatry.

[29]  D. Maclean,et al.  Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[30]  R. Bland,et al.  Mortality in a Cohort of Patients with Schizophrenia: A Record Linkage Study* , 1991, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[31]  G. Reaven.  Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[32]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[33]  P. Allebeck,et al.  Mortality in schizophrenia. A ten-year follow-up based on the Stockholm County inpatient register. , 1986, Archives of general psychiatry.

[34]  B. O'Shea,et al.  Excess mortality among psychiatric patients. , 1985, JAMA.

[35]  D. Black,et al.  Excess mortality among psychiatric patients. The Iowa Record-Linkage Study. , 1985, JAMA.

[36]  L. Dixon,et al.  Prevalence and correlates of diabetes in national schizophrenia samples. , 2000, Schizophrenia bulletin.

[37]  L. Goldman.  Medical illness in patients with schizophrenia. , 1999, The Journal of clinical psychiatry.

[38]  P. Decina,et al.  Diabetes mellitus in schizophrenic patients. , 1996, Comprehensive psychiatry.

[39]  G. Reaven.  Role of insulin resistance in human disease (syndrome X): an expanded definition. , 1993, Annual review of medicine.